HER2 Mutation

AUG 12, 2026 · PHASE 1/2 TRIAL

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

ClinicalTrials.gov

This is a first-in-human Phase 1/2 trial registration with no results reported; the study is actively recruiting and designed to establish safety, tolerability, and preliminary efficacy of a novel dual EGFR/HER2 inhibitor in advanced NSCLC.